A new tuberculosis (TB) medication includes the active ingredient bedaquiline. Sirturo is a brand name for a drug that belongs to the diarylquinoline class of drugs. Bedaquiline is a diarylquinoline antimycobacterial drug that works by blocking an enzyme within the bacteria that cause TB. It prevents the proton pump of mycobacterial adenosine 5′-triphosphate (ATP) synthase. Bedaquiline is metabolized in hepatic form and eliminated in the feces. Bedaquiline is effective and safe in treating multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) patients. This drug treatment regimen was well supported and tended to a good result in this clinically relevant patient associated with MDR-TB.
Jakeman B, Gross B, Fortune D, Babb S, Tinker D, Bachyrycz A. Evaluation of a pharmacist-performed tuberculosis testing initiative in New Mexico. J Am Pharmac Assoc 2015;55(3):307–312.
Steingart KR, Flores LL, Dendukuri N, Schiller I, Laal S, Ramsay A, et al. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis. PLoS Med 2011;8(8):e1001062.